Inhibrx Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company with two principal clinical programs, ozekibart (INBRX-109) and INBRX-106. Form 8-K reports furnish financial results, Regulation FD presentations, and clinical updates covering oncology studies in chondrosarcoma, colorectal cancer, Ewing sarcoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
The company’s proxy materials describe annual meeting matters, board elections, executive compensation and equity incentive governance. Its filings also identify Inhibrx Biosciences as an emerging growth company and provide formal disclosures on operating results, pipeline development, capital resources, risk factors, and the completed 2024 separation from Inhibrx, Inc.
Inhibrx Biosciences, Inc. is asking stockholders to vote at its virtual-only 2026 Annual Meeting on June 3, 2026. Stockholders will elect two Class II directors, Douglas G. Forsyth and Kimberly Manhard, to serve until 2029 and ratify BDO USA, P.C. as independent auditor for 2026.
The record date is April 7, 2026, when 14,607,286 common shares were outstanding and entitled to one vote each. The proxy also details board structure, committee memberships, director pay, and executive compensation, including 2025 total pay of $2,892,473 for CEO Mark P. Lappe, $923,696 for CFO Kelly D. Deck, and $1,435,940 for President David J. Matly.
Inhibrx Biosciences, Inc. reported updated interim results from its Phase 1/2 trial of ozekibart (INBRX-109) plus FOLFIRI in heavily pretreated colorectal cancer. Among 45 evaluable patients, objective response rate was 20% per RECIST v1.1, versus historical standards of care with 1–6% response rates, and nearly half of responses lasted more than six months.
Median progression-free survival was 5.5 months, with 42% of patients progression-free at six months and an overall disease control rate of 87%. Safety remained manageable, with mostly Grade 1–2 diarrhea, fatigue and nausea and no significant liver toxicity despite 68% of patients having baseline liver metastases.
Inhibrx plans to meet the FDA in the second half of 2026 about a first-line registrational colorectal cancer trial and possible accelerated pathways in fourth-line colorectal cancer and refractory Ewing sarcoma. The company also submitted a BLA for ozekibart in conventional chondrosarcoma in April 2026.
Inhibrx Biosciences, Inc. reported fourth quarter and full-year 2025 results and outlined key 2026 clinical milestones. The company is now focused on two clinical programs, ozekibart (INBRX-109) and INBRX-106, following the prior sale of INBRX-101 and spin-off from its former parent.
For 2025, Inhibrx recorded a net loss of $140.1 million, or $9.04 per share, compared with net income of $1.7 billion in 2024, which had included a large one-time gain from the 101 Transaction. Research and development expenses fell to $113.0 million from $203.7 million, while general and administrative expenses declined to $23.3 million from $127.9 million as transaction- and litigation-related costs rolled off.
As of December 31, 2025, cash and cash equivalents were $124.2 million. On March 18, 2026, the company amended its loan agreement with Oxford Finance and received gross proceeds of $75.0 million. Inhibrx expects to submit a BLA for ozekibart in early Q2 2026 and to report multiple ozekibart and INBRX-106 data readouts through 2026.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on engineered biologics for difficult cancers, built around proprietary single-domain antibody and multispecific platforms. Following a 2024 spin-off from its former parent after a Sanofi transaction, the company now centers on two lead programs, ozekibart (INBRX-109) and INBRX-106.
Ozekibart, a tetravalent DR5 agonist, showed encouraging activity in colorectal cancer, Ewing sarcoma, and chondrosarcoma, including positive results from the randomized ChonDRAgon trial, where it more than doubled median progression-free survival versus placebo in advanced chondrosarcoma. Inhibrx plans a biologics license application in early second quarter 2026.
INBRX-106, a hexavalent OX40 agonist, is being tested alone and with KEYTRUDA in multiple solid tumors. Early combination data in non-small cell lung cancer and head and neck cancer showed responses after prior checkpoint exposure, and a seamless Phase 2/3 trial in first-line head and neck cancer is underway. The company reports broad global patent coverage across its molecules and platforms.
Inhibrx Biosciences, Inc. furnished an updated investor presentation outlining its oncology pipeline, recent clinical results and financial position. The company reported key metrics as of September 30, 2025, including $153 cash and cash equivalents, 14 common stock outstanding and 19 fully diluted outstanding.
The presentation highlights ozekibart (INBRX-109) registrational trial data in chondrosarcoma, where median progression-free survival reached 5.52 months versus 2.66 months for placebo, with a hazard ratio of 0.479 and P<0.0001. Disease control rate was 54% versus 27.5%.
Early phase 1/2 data for ozekibart in late-line colorectal cancer showed a 92% disease control rate and 23% objective response rate in combination with FOLFIRI, while in Ewing sarcoma, ozekibart plus irinotecan/temozolomide achieved a 92% disease control rate and 64% objective response rate. The presentation also details INBRX-106, a hexavalent OX40 agonist being advanced into a seamless phase 2/3 trial in first-line head and neck squamous cell carcinoma with pembrolizumab.
Inhibrx Biosciences, Inc. received an updated Schedule 13G/A showing that investment entities affiliated with Viking Global Investors collectively report beneficial ownership of 1,454,608 shares of common stock, or 9.99% of the company. This includes shares held by Viking Global Opportunities Illiquid Investments Sub-Master LP, KAVRA 104 LLC and Viking Global Opportunities Drawdown (Aggregator) LP, plus 16,903 shares that VGOP may acquire through low‑priced warrants.
The ownership percentages are calculated using 14,543,738 shares outstanding as of November 7, 2025 and the currently exercisable warrant shares. All reporting persons disclose shared, and no sole, voting and dispositive power over their positions. They also certify that the securities are not held for the purpose of changing or influencing control of Inhibrx Biosciences.
Morgan Stanley and its affiliate Morgan Stanley Capital Services LLC have filed a Schedule 13G reporting beneficial ownership of Inhibrx Biosciences, Inc. common stock as of 12/31/2025. Morgan Stanley reports beneficial ownership of 1,155,416 shares, representing 7.9% of the outstanding common stock.
Morgan Stanley Capital Services LLC reports beneficial ownership of 918,011 shares, or 6.3% of the class, with shared voting and dispositive power over those shares. The securities are certified as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Inhibrx Biosciences.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Inhibrx Biosciences, Inc. common stock. BlackRock reports beneficial ownership of 768,130 shares, representing 5.3% of the company’s outstanding common stock as of the event date. BlackRock has sole voting power over 759,521 shares and sole dispositive power over 768,130 shares, with no shared voting or dispositive power.
The filing states that these securities are held in the ordinary course of business and are not held for the purpose of changing or influencing control of Inhibrx Biosciences. Various underlying clients or investors have rights to dividends or sale proceeds, but no single underlying holder has more than 5% of the total outstanding common shares.
Inhibrx Biosciences, Inc. reported clinical development updates for its immuno‑oncology programs INBRX‑106 and ozekibart. For INBRX‑106, it has enrolled 46 of 60 patients in the randomized Phase 2 portion of a Phase 2/3 trial in combination with Keytruda as a first‑line treatment for unresectable or metastatic head and neck squamous cell carcinoma, with completion of Phase 2 enrollment expected in the first quarter of 2026. A separate Phase 1/2 cohort of 34 patients with checkpoint inhibitor refractory or relapsed non‑small cell lung cancer in combination with Keytruda has completed enrollment.
Current datasets for both head and neck cancer and lung cancer are not yet mature enough to draw conclusions, and Inhibrx expects data in the second half of 2026 to assess the viability of INBRX‑106 in combination with Keytruda. For ozekibart, Inhibrx has completed enrollment of 44 patients in a Phase 1/2 expansion cohort in advanced colorectal cancer, with progression‑free survival data expected to mature in the second quarter of 2026, and it aims to complete enrollment in an Ewing sarcoma trial in the second quarter of 2026 and then discuss a potential accelerated approval pathway with the FDA in the second half of 2026 if current response trends continue.